Evidence map›Paper›PMID 39511587›Full record

ArticleMicrobiome2024

Multimodal analysis identifies microbiome changes linked to stem cell transplantation-associated diseases.

Alejandro Artacho, Cintya González-Torres, Nuria Gómez-Cebrián, Paula Moles-Poveda, Javier Pons, Nuria Jiménez, María Jinglei Casanova, Juan Montoro, Aitana Balaguer, Marta Villalba and 4 more

Abstract read
In one paragraph

Article in Microbiome, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Enteral versus parenteral nutrition in auto-HCT: a randomized controlled trial on clinical outcomes and gut microbiome dynamics.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Gut microbiota and acute graft-versus-host disease.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alejandro Artacho *Fundación Para El Fomento de La Investigación Sanitaria y Biomédica de La Comunitat Valenciana-FISABIO, Valencia, Spain.
Cintya González-Torres *Fundación Para El Fomento de La Investigación Sanitaria y Biomédica de La Comunitat Valenciana-FISABIO, Valencia, Spain.
Nuria Gómez-CebriánDrug Discovery Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Paula Moles-PovedaHematology Department, Hospital Universitari I Politècnic La Fe, Valencia, Spain.
Javier PonsFundación Para El Fomento de La Investigación Sanitaria y Biomédica de La Comunitat Valenciana-FISABIO, Valencia, Spain.
Nuria JiménezFundación Para El Fomento de La Investigación Sanitaria y Biomédica de La Comunitat Valenciana-FISABIO, Valencia, Spain.
María Jinglei CasanovaHematology Department, Hospital Universitari I Politècnic La Fe, Valencia, Spain.
Juan MontoroHematology Department, Hospital Universitari I Politècnic La Fe, Valencia, Spain.
Aitana BalaguerHematology Department, Hospital Universitari I Politècnic La Fe, Valencia, Spain.
Marta VillalbaHematology Department, Hospital Universitari I Politècnic La Fe, Valencia, Spain.
Pedro ChorãoHematology Department, Hospital Universitari I Politècnic La Fe, Valencia, Spain.
Leonor Puchades-CarrascoDrug Discovery Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Jaime SanzHematology Department, Hospital Universitari I Politècnic La Fe, Valencia, Spain. jaime.sanz@uv.es.
Carles UbedaFundación Para El Fomento de La Investigación Sanitaria y Biomédica de La Comunitat Valenciana-FISABIO, Valencia, Spain. carles.ubeda@fisabio.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the most efficient therapeutic options available to cure many hematological malignancies. However, severe complications derived from this procedure, including graft-versus-host disease (GVHD) and infections, can limit its success and negatively impact survival. Previous studies have shown that alterations in the microbiome are associated with the development of allo-HSCT-derived complications. However, most studies relied on single techniques that can only analyze a unique aspect of the microbiome, which hinders our ability to understand how microbiome alterations drive allo-HSCT-associated diseases.

resultsHere, we have applied multiple "omic" techniques (16S rRNA and shotgun sequencing, targeted and un-targeted metabolomics) in combination with machine learning approaches to define the most significant microbiome changes following allo-HSCT at multiple modalities (bacterial taxa, encoded functions, and derived metabolites). In addition, multivariate approaches were applied to study interactions among the various microbiome modalities (the interactome). Our results show that the microbiome of transplanted patients exhibits substantial changes in all studied modalities. These include depletion of beneficial microbes, mainly from the Clostridiales order, loss of their bacterial encoded functions required for the synthesis of key metabolites, and a reduction in metabolic end products such as short chain fatty acids (SCFAs). These changes were followed by an expansion of bacteria that frequently cause infections after allo-HSCT, including several Staphylococcus species, which benefit from the reduction of bacteriostatic SCFAs. Additionally, we found specific alterations in all microbiome modalities that distinguished those patients who subsequently developed GVHD, including depletion of anti-inflammatory commensals, protective reactive oxygen detoxifying enzymes, and immunoregulatory metabolites such as acetate or malonate. Moreover, extensive shifts in the homeostatic relationship between bacteria and their metabolic products (e.g., Faecalibacterium and butyrate) were detected mainly in patients who later developed GVHD.

conclusionsWe have identified specific microbiome changes at different modalities (microbial taxa, their encoded genes, and synthetized metabolites) and at the interface between them (the interactome) that precede the development of complications associated with allo-HSCT. These identified microbial features provide novel targets for the design of microbiome-based strategies to prevent diseases associated with stem cell transplantation. Video Abstract.

Indexed as

BacteriaGraft vs Host DiseaseHematopoietic Stem Cell TransplantationRNA, Ribosomal, 16SAdultFatty Acids, VolatileFemaleGastrointestinal MicrobiomeHumansMachine LearningMaleMetabolomicsMicrobiotaMiddle AgedTransplantation, HomologousFatty Acids, VolatileRNA, Ribosomal, 16S

Identifiers

PMID39511587
PMCPMC11542268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.